This poster is published under an
open license. Please read the
disclaimer for further details.
Type:
Educational Exhibit
Keywords:
Staging, Diagnostic procedure, MR-Diffusion/Perfusion, MR, Genital / Reproductive system male, Pelvis, Oncology, Multidisciplinary cancer care, Neoplasia
Authors:
I. Abreu1, D. Roriz1, A. P. Pissarra1, �. Moreira1, C. B. Marques1, F. Caseiro Alves2; 1Coimbra/PT, 2Coimbra, Coimbra/PT
DOI:
10.1594/ecr2017/C-1846
Conclusion
PI-RADS v2 should be used in conjunction with other resources in the evaluation and risk assessment of patients with suspected PCa prior to or after transrectal ultrasound biopsy.
Improved risk management with better identification of significant versus insignificant cancers may lead to more specific and individualised treatment options and less overtreatment of indolent disease.
Outcome data derived from MRI-targeted biopsies are needed to develop new nomograms that define patients’ risk on the basis of clinical variables in combination with overall PI-RADS v2 assessment categories.
PI-RADS v2 needs to be tested and validated in different clinical scenarios.
Validation should be undertaken using MR-targeted biopsy,
systematic biopsy (saturation or template techniques),
and whole-mount histopathology.
Long-term follow-up data are also needed before we can conclude that PI-RADS v2 is effective in directing patient management and for improving outcomes of patients with suspected PCa.
Radiologists must be properly trained to use PI-RADS v2 and the system must be tested and validated in different clinical scenarios,
including its sensitivity and specificity for clinically significant disease,
its reproducibility among readers with different experience levels and between centres,
and its role in clinical decisions.